Table 2.
5-year outcomes of classical Hodgkin lymphoma.
| 5-year EFS N = 939 | 95% confidence interval | p value | |
|---|---|---|---|
| Age group | |||
| <50 years | 80.21% | 76.91%–83.65% | 0.0093 |
| ≥50 years | 73.26% | 67.61%–79.38% | |
| Gender | |||
| Male | 77.04% | 73.42%–80.84% | 0.64 |
| Female | 80.44% | 75.79%–85.38% | |
| Stage | |||
| I | 82.13% | 74.41%–90.65% | 0.<00019 |
| II | 83.96% | 79.75%–88.39% | |
| III | 78.94% | 73.61%–84.65% | |
| IV | 67.56% | 61.21%–74.58% | |
| Early stage | |||
| Favorable | 84.45% | 75.05%–95.03% | 0.94 |
| Unfavorable | 83.60% | 79.58%–87.62% | |
| Advanced-stage Hodgkin’s IPI | |||
| Score 0–3 | 76.56% | 71.63%–81.84% | 0.013 |
| Score 4–7 | 65.48% | 57.47%–74.61% | |
| Comorbidities | |||
| No | 78.27% | 74.48%–82.24% | 0.068 |
| Yes | 73.71% | 65.80%–82.57% | |
| B symptoms | |||
| No | 83.16% | 79.39%–87.10% | 0.00032 |
| Yes | 73.53% | 69.30%–78.03% | |
| Stage groups | |||
| Early | 83.53% | 79.80%–87.44% | 0.00087 |
| Advanced | 73.55% | 69.33%–78.02% | |
| Treatment groups | |||
|
79.97% | 77.08%–82.97% | <0.0001 |
| 47.94% | 35.24%–65.22% | ||
| ABVD in age group | |||
| <50 | 80.86% | 77.57%–84.30% | 0.16 |
| >50 | 77.33% | 71.49%–83.64% | |
| Chemotherapy - RT | |||
| Chemotherapy + RT | 75.85% | 69.83%–82.39% | 0.67 |
| Chemotherapy only | 79.00% | 75.75%–82.39% | |
| Chemotherapy - RT in the early stage | |||
| 4 cycles | 66.33% | 55.67%–79.03% | <0.0001 |
| 4 cycles + RT | 88.57% | 80.92%–96.93% | |
| 6 cycles | 89.67% | 85.26%–94.31% | |
| 6 cycles + RT | 77.58% | 67.36%–89.35% | |
| Interim PET groups | |||
| CR | 90.72% | 86.69%–94.95% | <0.0001 |
| No CR | 69.30% | 60.97%–78.76% | |
| End of 1st line | |||
| CR | 88.85% | 86.34%–91.44% | <0.0001 |
| No CR | 35.38% | 27.38%–45.71% | |
| 5-year EFS | 78.24% | 75.36%–81.24% | |
| 5-year OS | 83.63% | 80.86%–86.49% | |
| Second line-EFS | 60.66% | 49.62%–74.15% |
RT, radiotherapy; CR, complete response; EFS, event-free survival; OS, overall survival.